PE20080906A1 - HETEROARYL DERIVATIVES AS CYTOKINE INHIBITORS - Google Patents

HETEROARYL DERIVATIVES AS CYTOKINE INHIBITORS

Info

Publication number
PE20080906A1
PE20080906A1 PE2007001096A PE2007001096A PE20080906A1 PE 20080906 A1 PE20080906 A1 PE 20080906A1 PE 2007001096 A PE2007001096 A PE 2007001096A PE 2007001096 A PE2007001096 A PE 2007001096A PE 20080906 A1 PE20080906 A1 PE 20080906A1
Authority
PE
Peru
Prior art keywords
alkyl
ter
aryl
phenyl
butyl
Prior art date
Application number
PE2007001096A
Other languages
Spanish (es)
Inventor
Erik Boman
Justin Ernst
Montalban Antonio Garrido
Christopher J Larson
Christopher Lum
Yazhong Pei
Lubomir Sebo
Jan Urban
Zhijun Wang
Jay Zhu
Original Assignee
Kemia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kemia Inc filed Critical Kemia Inc
Publication of PE20080906A1 publication Critical patent/PE20080906A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems

Abstract

REFERIDA A UN COMPUESTO HETEROARILO DE FORMULA (I), DONDE X ES CH, N O NO; Y ES CH, N, NO, CON LA CONDICION DE QUE X E Y NO SEAN AMBOS CH O NO; A ES F, Cl, NR2, ALQUILO C1-C3, ENTRE OTROS; G ES UN GRUPO ARILO O HETEROARILO, DONDE G SE SUSTITUYE POR UNO OMAS R1, R2 O R3; Ar ES UN GRUPO ARILO O HETEROARILO DE 6 MIEMBROS; L1 ES C(O)NH; L2 ES UN ENLACE COVALENTE, (CR'2)s, (CR'2)nO(CR'2)t, ENTRE OTROS; Q ES ALQUILO, CICLOALQUILO, ARILO, ENTRE OTROS; R1 ES F, Cl, NR2, CN, ENTRE OTROS; R2 ES Cl, CN, NO2, OR, ENTRE OTROS; R3 ES ALQUILO, ALQUENILO, ALQUINILO, ENTRE OTROS; R ES H, ALQUILO C1-C6, ENTRE OTROS; R' ES H, ALQUILO, CICLOALQUILO, ENTRE OTROS; n ES 0, 1 O 2; s ES 1, 2 O3; t ES 0, 1 O 2; CON LA CONDICION DE QUE EL COMPUESTO NO SEA 5-(BIFENIL-4-IL)-6-CLORO-N-(6-METOXIPIRIDIN-3-IL)NICOTINAMIDA. SON COMPUESTOS PREFERIDOS: 3-TER-BUTIL-5-CIANO-N-(6-METIL-5-(3-(NEOPENTILCARBAMOIL)FENIL)-PIRIDIN-3-IL)BENZAMIDA, N-(5-(4-(BENCILOXI)FENIL)-6-METILPIRIDIN-3-IL)-3-TER-BUTIL-5-CIANOBENZAMIDA, 3-TER-BUTIL-5-CIANO-N-(5-(4-(3,3-DIMETIL-2-OXOBUTOXI)FENIL)-6-METILPIRIDIN-3-IL)BENZAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACIUON. DICHOS COMPUESTOS SON INHIBIDORES DE CITOCINA Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES, INFLAMATORIAS, CANCER, ENTRE OTRASREFERRING TO A HETEROARYL COMPOUND OF FORMULA (I), WHERE X IS CH, N OR NO; Y IS CH, N, NO, WITH THE CONDITION THAT X AND Y ARE NOT BOTH CH OR NOT; A IS F, Cl, NR2, C1-C3 ALKYL, AMONG OTHERS; G IS AN ARYL OR HETEROARYL GROUP, WHERE G IS REPLACED BY ONE OMAS R1, R2 OR R3; Ar IS AN ARYL OR HETEROARY GROUP OF 6 MEMBERS; L1 IS C (O) NH; L2 IS A COVALENT LINK, (CR'2) s, (CR'2) nO (CR'2) t, AMONG OTHERS; Q IS ALKYL, CYCLOALKYL, ARYL, AMONG OTHERS; R1 IS F, Cl, NR2, CN, AMONG OTHERS; R2 IS Cl, CN, NO2, OR, AMONG OTHERS; R3 IS RENTAL, ALKENYL, ALKINYL, AMONG OTHERS; R IS H, C1-C6 ALKYL, AMONG OTHERS; R 'IS H, ALKYL, CYCLOALKYL, AMONG OTHERS; n IS 0, 1 O 2; s IS 1,2 O3; t IS 0, 1 O 2; WITH THE CONDITION THAT THE COMPOUND IS NOT 5- (BIPHENYL-4-IL) -6-CHLORO-N- (6-METOXIPIRIDIN-3-IL) NICOTINAMIDE. PREFERRED COMPOUNDS ARE: 3-TER-BUTYL-5-CYAN-N- (6-METHYL-5- (3- (NEOPENTILCARBAMOIL) PHENYL) -PYRIDIN-3-IL) BENZAMIDE, N- (5- (4- (BENZYLOXY ) PHENYL) -6-METHYLPYRIDIN-3-IL) -3-TER-BUTYL-5-CYANOBENZAMIDE, 3-TER-BUTYL-5-CYANE-N- (5- (4- (3,3-DIMETHYL-2- OXOBUTOXI) PHENYL) -6-METHYLPYRIDIN-3-IL) BENZAMIDE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION AND A PREPARATION PROCEDURE. SUCH COMPOUNDS ARE INHIBITORS OF CYTOKINE AND ARE USEFUL IN THE TREATMENT OF AUTOIMMUNE, INFLAMMATORY, CANCER, AMONG OTHERS

PE2007001096A 2006-08-17 2007-08-15 HETEROARYL DERIVATIVES AS CYTOKINE INHIBITORS PE20080906A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83879506P 2006-08-17 2006-08-17
US89147007P 2007-02-23 2007-02-23

Publications (1)

Publication Number Publication Date
PE20080906A1 true PE20080906A1 (en) 2008-07-05

Family

ID=39082322

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001096A PE20080906A1 (en) 2006-08-17 2007-08-15 HETEROARYL DERIVATIVES AS CYTOKINE INHIBITORS

Country Status (5)

Country Link
AR (1) AR062427A1 (en)
CL (1) CL2007002375A1 (en)
PE (1) PE20080906A1 (en)
TW (1) TW200815422A (en)
WO (1) WO2008021388A1 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006272978B2 (en) 2005-07-26 2012-06-07 Bial - Portela & Ca, S.A. Nitrocatechol derivatives as COMT inhibitors
TW200804288A (en) 2005-12-12 2008-01-16 Astrazeneca Ab Alkylsulphonamide quinolines
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
RU2518483C2 (en) 2007-01-31 2014-06-10 Биал-Портела Энд Ка, С.А. Comt inhibitor dosage regimen
CN101669030B (en) 2007-03-08 2016-01-13 小利兰·斯坦福大学托管委员会 Mitochondrial aldehyde dehydrogenase-2 modulators and its using method
BRPI0810202A2 (en) 2007-05-03 2014-10-21 Pfizer Ltd PYRIDINE DERIVATIVES
CL2008001943A1 (en) 2007-07-02 2009-09-11 Boehringer Ingelheim Int Compounds derived from phenyl-triazole, inhibitors of specific signal enzymes that participate in the control of cell proliferation; pharmaceutical composition comprising said compounds; and its use to treat cancer, infections, inflammatory and autoimmune diseases.
TWI446904B (en) 2007-11-01 2014-08-01 Acucela Inc Amine derivative compounds for treating ophthalmic diseases and disorders
JP2011514380A (en) 2008-03-17 2011-05-06 バイアル−ポルテラ アンド シーエー，エス．エー． 5- [3- (2,5-dichloro-4,6-dimethyl-1-oxy-pyridin-3-yl) [1,2,4] oxadiazol-5-yl] -3-nitrobenzene-1, 2-Diol crystal form
US20110144107A1 (en) * 2008-06-11 2011-06-16 Irm Llc Compounds and compositions useful for the treatment of malaria
AR073501A1 (en) 2008-09-08 2010-11-10 Boehringer Ingelheim Int PYRIMID DERIVATIVES [5,4-D] PYRIMIDINE INHIBITORS OF THYROSINOQUINASE
JP2012502048A (en) 2008-09-08 2012-01-26 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ Modulators of aldehyde dehydrogenase activity and methods of use thereof
BRPI0920608A2 (en) * 2008-09-29 2019-09-24 Boehringer Ingelheim Int chemical compounds
US8389522B2 (en) * 2008-10-28 2013-03-05 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
JP2012513410A (en) 2008-12-23 2012-06-14 アボット・ラボラトリーズ Antiviral compounds
RU2505540C2 (en) 2008-12-23 2014-01-27 Эббви Инк. Antiviral compounds
WO2010094695A1 (en) 2009-02-17 2010-08-26 Boehringer Ingelheim International Gmbh Pyrimido [5,4-d] pyrimidine derivatives for the inhibition of tyrosine kinases
BRPI1014865B1 (en) 2009-04-01 2020-03-17 Bial - Portela & C.A., S.A. Composition comprising granules comprising 2,5-dichloro-3- (5- (3,4-dihydroxy-5-nitrophenyl) - 1,2,4-oxadiazol-3-yl) - 4,6-dimethylpyridine 1-oxide and pharmaceutical formulation
MX2011010905A (en) 2009-04-15 2011-11-01 Abbott Lab Anti-viral compounds.
FR2953519B1 (en) 2009-12-08 2012-02-10 Commissariat Energie Atomique NOVEL CHEMICAL COMPOUNDS SUITABLE FOR COMPLEXING AT LEAST ONE METAL ELEMENT AND COORDINATION COMPLEX THEREFROM
WO2011117382A1 (en) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh Pyridyltriazoles
WO2011117381A1 (en) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh B-raf kinase inhibitors
JP5722892B2 (en) * 2010-07-15 2015-05-27 武田薬品工業株式会社 Heterocyclic compounds
US8410107B2 (en) * 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
SI2791134T1 (en) 2011-12-13 2020-01-31 Bial - Portela & Ca S.A. Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor
KR20150092162A (en) * 2012-12-10 2015-08-12 에프. 호프만-라 로슈 아게 BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS
JP6410790B2 (en) 2013-03-14 2018-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Mitochondrial aldehyde dehydrogenase-2 modulator and method of use thereof
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9233961B2 (en) 2013-03-15 2016-01-12 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9186361B2 (en) 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
EP2986293A1 (en) 2013-04-19 2016-02-24 Astrazeneca AB A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)
AU2014364565B2 (en) 2013-12-19 2017-06-15 Novartis Ag [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis
CN105873438A (en) * 2014-01-31 2016-08-17 日产化学工业株式会社 Liquid pesticide composition
RU2017120184A (en) 2014-11-28 2018-12-28 БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. DRUGS TO DELAY THE COURSE OF PARKINSON'S DISEASE
CN104926738B (en) * 2015-06-08 2017-05-24 南京农业大学 Application of 1,2,3-triazole-4-hydrazide derivatives to preparation of agricultural bactericide
EP3394059B1 (en) 2015-12-23 2020-11-25 Chiesi Farmaceutici S.p.A. 1-(3-tert-butyl-phenyl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro- naphthalen-1-yl)-urea derivatives and their use as p38 mapk inhibitors
CA3016161A1 (en) 2016-03-03 2017-09-08 Cornell University Small molecule ire1-alpha inhibitors
CA3039203A1 (en) 2016-10-03 2018-04-12 Sigilon Therapeutics, Inc. Compounds, devices, and uses thereof
US11571429B2 (en) * 2017-05-23 2023-02-07 Upexmed Co. Ltd. Method and compounds for treating peripheral neuropathy
LT3691620T (en) 2017-10-05 2022-09-26 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN111220737A (en) * 2018-11-27 2020-06-02 罗欣药业(上海)有限公司 Method for separating ezetimibe and optical isomer thereof
EP3932912A4 (en) * 2019-02-28 2022-09-07 Osaka University Protein and/or peptide modification molecule
CN110095463B (en) * 2019-03-15 2021-10-22 中国人民解放军陆军军医大学第二附属医院 Kit for qualitative detection of chyle
TW202322824A (en) 2020-02-18 2023-06-16 美商基利科學股份有限公司 Antiviral compounds
CN116761801A (en) * 2021-03-12 2023-09-15 四川科伦博泰生物医药股份有限公司 Heterocyclic compounds having protein kinase inhibitory activity, pharmaceutical compositions containing the same, and methods of preparing and using the same
CN117120444A (en) 2021-04-16 2023-11-24 吉利德科学公司 Method for preparing carbanucleoside using amide
CN115089590B (en) * 2022-06-13 2023-05-12 同济大学 Application of cyclopentyl triazolopyrimidine as pharmaceutical ingredient in hepatitis drugs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6196201A (en) * 2000-05-25 2001-12-03 Merck Frosst Canada Inc Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor

Also Published As

Publication number Publication date
AR062427A1 (en) 2008-11-05
TW200815422A (en) 2008-04-01
WO2008021388A1 (en) 2008-02-21
CL2007002375A1 (en) 2008-04-04

Similar Documents

Publication Publication Date Title
PE20080906A1 (en) HETEROARYL DERIVATIVES AS CYTOKINE INHIBITORS
RU2011106374A (en) CYCLIC INHIBITORS 11BETA-HYDROXYSTEROID-DEHYDROGENASE 1
PE20070189A1 (en) AMINO-5-HETEROARYL COMPOUND (5 MEMBERS) IMIDAZOLONE AND ITS USE FOR ß-SECRETASE MODULATION
PE20090601A1 (en) PYRIDIN-IL-OXY-PYRIDINES DERIVATIVES AS ALK5 INHIBITORS
PE20070855A1 (en) DERIVATIVES OF 4-AMINO-PYRROLOTRIAZINE SUBSTITUTE AS KINASE INHIBITORS
PE20070041A1 (en) PYRAZOLCARBOXYL ACID AMIDES
PE20091573A1 (en) HETEROCYCLIC DERIVATIVES OF UREA AS INHIBITORS OF DNA GIRASE AND / OR TOPOISOMERASE
PE20110294A1 (en) HETEROCYCLIC COMPOUNDS AS INHIBITORS OF SPECIFIC SIGNAL ENZYMES
PE20091842A1 (en) PYRROLIDINONES AS GLUCOKINASE ACTIVATORS
PE20060479A1 (en) HETEROARYL-ARYL-UREAS COMPOUNDS AS KINASE INHIBITORS
PE20120229A1 (en) HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PROTEASE ASPARTIC
PE20061124A1 (en) COMPOUNDS AND DERIVATIVES OF DIBENCIL AMINE
PE20070528A1 (en) HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE VANYLOID RECEPTOR OF SUBTYPE 1
ECSP066886A (en) COMPOUNDS AND METHODS FOR THE TREATMENT OF DISLIPIDEMIA
ECSP067013A (en) 2-QUINOLIL-OXAZOLES REPLACED USEFUL AS PDE INHIBITORS4
AR072166A1 (en) PIPERIDINE DERIVATIVE AND ITS USE AS A SUPERIOR RENINA INHIBITOR
CO5700757A2 (en) DERIVATIVES OF (3-OXO-3,4-DIHIDRO-QUINOXALIN-2-IL-AMINO) -BENZAMIDE AND RELATED COMPOUND, AS INHIBITORS OF GLUCOGEN PHOSPHORILASE FOR THE TREATMENT OF DIABETES AND OBESITY
PE20091952A1 (en) TIAZOLE AND OXAZOLE COMPOUNDS OF BENZENE SULFONAMIDE
CO5611147A2 (en) USEFUL NICOTINAMIDE DERIVATIVES AS INHIBITORS P38
PE20090641A1 (en) HETERO CYCLIC AMIDES
PE20140913A1 (en) NAMPT AND ROCK INHIBITORS
UA98116C2 (en) Isoxazolines, composition, use thereof, methods of production and intermediates
EA200601896A1 (en) PROLINE DERIVATIVES AND THEIR APPLICATION AS DIPEPTIDYLPEPTIDASE IV INHIBITORS
AR087196A1 (en) PESTICIDED METHODS THAT USE REPLACED 3-PIRIDIL TIAZOL COMPOUNDS AND DERIVATIVES TO COMBAT ANIMAL PESTS II
PE20140863A1 (en) BENZENE COMPOUNDS REPLACED WITH ARYL OR HETEROARYL

Legal Events

Date Code Title Description
FX Voluntary withdrawal